Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-9041Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kayki-Mutlu, Gizem | - |
| dc.contributor.author | Aksoyalp, Zinnet Sevval | - |
| dc.contributor.author | Wojnowski, Leszek | - |
| dc.contributor.author | Michel, Martin C. | - |
| dc.date.accessioned | 2023-04-27T09:20:09Z | - |
| dc.date.available | 2023-04-27T09:20:09Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/9058 | - |
| dc.description.abstract | While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly approved drugs in 2022 are considerably less than the 53 and 50 new drugs approved in 2020 and 2021, respectively, and less than the rolling 10-year average of 43. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify two “first-in-indication” (ganaxolon and teplizumab), 20 (54%) “first-in-class,” and 17 (46%) “next-in-class” drugs. By treatment area, rare diseases and cancer drugs were once again the most prevalent (partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics). | en_GB |
| dc.description.sponsorship | Deutsche Forschungsgemeinschaft (DFG)|491381577|Open-Access-Publikationskosten 2022–2024 Universität Mainz - Universitätsmedizin | - |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | A year in pharmacology : new drugs approved by the US Food and Drug Administration in 2022 | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-9041 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Naunyn-Schmiedeberg's archives of pharmacology | de |
| jgu.journal.volume | Version of Record (VoR) | de |
| jgu.publisher.year | 2023 | - |
| jgu.publisher.name | Springer | de |
| jgu.publisher.place | Berlin u.a. | de |
| jgu.publisher.issn | 1432-1912 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1007/s00210-023-02465-x | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | DFG-491381577-H | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | a_year_in_pharmacology__new_d-20230424112140624.pdf | 752.88 kB | Adobe PDF | View/Open |